Quantum-First Trial: FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( <i>FLT3</i>-ITD)-Specific Measurable Residual Disease (MRD) Clearance Assessed through Induction (IND) and Consolidation (CONS) Is Associated with Improved Overall Survival (OS) in Newly Diagnosed (nd) <i>FLT3</i>-ITD+ AML Patients (pts)
Alexander E. Perl(University of Pennsylvania), Mark J. Levis(Sidney Kimmel Cancer Center), Po‐Nan Wang(Chang Gung Memorial Hospital), Jörge E. Cortes(Augusta University Health), Arnaud Lesegretain(Daiichi Sankyo (United States)), Radovan Vrhovac(University Hospital Centre Zagreb), Harry P. Erba(Michigan Center for Translational Pathology), Richard F. Schlenk(German Cancer Research Center), Mikkael A. Sekeres(University of Miami), Elżbieta Patkowska(Institute for Transfusion Medicine), Jaime E. Connolly Rohrbach(Daiichi Sankyo (United States)), Yasser Mostafa Kamel(Daiichi Sankyo (United States)), Karima Imadalou(Daiichi Sankyo (United States)), Sergio Amadori(Polyclinic Medical Center), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Hee‐Je Kim(St. Mary's Hospital), Павел Зак(University Hospital Hradec Králové), Li Liu(Daiichi Sankyo (United States)), Hervé Dombret(University of London Institute in Paris), Ken C. N. Chang(Daiichi Sankyo (United States)), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 5
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k